Rna Diagnostics is dedicated to improving the management of cancer treatments. The RNA Disruption Assay will provide physicians with an evaluation of how patients are responding to cancer treatments, in real time. If the cancer drugs are working, the physician and patient can continue with confidence. If the cancer drugs are not working well enough, physicians may consider alternate treatments. For patients, this means avoiding harmful side effects and an opportunity to improve outcomes. This is personalized medicine.
John Connolly
iGan Arabia invests in emerging companies with strong IP that can benefit the MENA healthcare systems and populations. With a focus on data-driven medical device and digital health technologies, we invest in dynamic management teams, empowering them to build impactful and highly scalable businesses.
Privacy Policy | © 2024 iGan Partners. All Rights Reserved.